These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7201887)

  • 1. Failure of clinical response to prostaglandin E1 in a cyanotic infant with congenital absence of the ductus arteriosus.
    Hamilton WT; Lacina SJ; Bharati S; Lev M; Arcilla RA
    Cathet Cardiovasc Diagn; 1982; 8(3):273-6. PubMed ID: 7201887
    [No Abstract]   [Full Text] [Related]  

  • 2. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT; Norton JB; Readinger RI; Sotomora RF
    J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
    [No Abstract]   [Full Text] [Related]  

  • 4. Care of the infant with ductus-dependent congenital heart disease receiving prostaglandin E1.
    Stachura L
    Issues Compr Pediatr Nurs; 1984; 7(4-5):203-15. PubMed ID: 6569057
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.
    Freed MD; Heymann MA; Lewis AB; Roehl SL; Kensey RC
    Circulation; 1981 Nov; 64(5):899-905. PubMed ID: 7285305
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of prostaglandin E1 for maintaining the patency of the ductus arteriosus.
    Noah ML
    Adv Prostaglandin Thromboxane Res; 1978; 4():355-62. PubMed ID: 347914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dilation of the ductus arteriosus by oral prostaglandin E1 derivative in cyanotic congenital heart diseases.
    Matsuura H; Saji T; Yamamoto S; Ishikita T; Aoki Y; Matsuo N
    Am Heart J; 1993 May; 125(5 Pt 1):1453-4. PubMed ID: 8480610
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B; Björkhem G; Lundström NR
    Lakartidningen; 1984 Oct; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: Emergency treatment of certain cyanotic heart defects with prostaglandin E2.
    Olley PM; Coceani F
    Br Heart J; 1976 Aug; 38(8):877. PubMed ID: 973917
    [No Abstract]   [Full Text] [Related]  

  • 12. [Value of prostaglandin E1 in the treatment of cyanotic congenital heart defects in infants].
    Dymnicka S; Bielińska B; Ereciński J; Machnowski W
    Pediatr Pol; 1981 Oct; 56(10):1243-8. PubMed ID: 7199703
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S; Nagai I; Yonei A; Sari A; Baba K
    Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease.
    Heymann MA
    Am Heart J; 1981 Jun; 101(6):837-43. PubMed ID: 7234660
    [No Abstract]   [Full Text] [Related]  

  • 15. [Value of prostaglandin E1 in cardiac malformations in the newborn infant].
    Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J
    Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of prostaglandin E1 and E2 in the management of neonatal heart disease.
    Olley PM; Coceani F; Rowe RD
    Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511
    [No Abstract]   [Full Text] [Related]  

  • 17. The morphology of the human newborn ductus arteriosus: a reappraisal of its structure and closure with special reference to prostaglandin E1 therapy.
    Silver MM; Freedom RM; Silver MD; Olley PM
    Hum Pathol; 1981 Dec; 12(12):1123-36. PubMed ID: 7199511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies.
    Heymann MA; Rudolph AM
    Adv Prostaglandin Thromboxane Res; 1978; 4():363-72. PubMed ID: 645512
    [No Abstract]   [Full Text] [Related]  

  • 19. Transient neonatal tricuspid regurgitation: possible relation with premature closure of the ductus arteriosus.
    Berry TE; Muster AJ; Paul MH
    J Am Coll Cardiol; 1983 Dec; 2(6):1178-82. PubMed ID: 6685153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 infusion: successful initial treatment.
    Linday L; Levin AR; Reitman M; Engle MA
    N Y State J Med; 1981 Feb; 81(2):218-21. PubMed ID: 6936640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.